Log in

Relevant bibliographies by topics / Daclatasvir / Journal articles

To see the other types of publications on this topic, follow the link: Daclatasvir.

Journal articles on the topic 'Daclatasvir'

Author: Grafiati

Published: 9 March 2023

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Daclatasvir.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Sacramento, Carolina Q., Natalia Fintelman-Rodrigues, Jairo R. Temerozo, et al. "In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19." Journal of Antimicrobial Chemotherapy 76, no. 7 (2021): 1874–85. http://dx.doi.org/10.1093/jac/dkab072.

Full text

Abstract:

Abstract Background Current approaches of drug repurposing against COVID-19 have not proven overwhelmingly successful and the SARS-CoV-2 pandemic continues to cause major global mortality. SARS-CoV-2 nsp12, its RNA polymerase, shares homology in the nucleotide uptake channel with the HCV orthologue enzyme NS5B. Besides, HCV enzyme NS5A has pleiotropic activities, such as RNA binding, that are shared with various SARS-CoV-2 proteins. Thus, anti-HCV NS5B and NS5A inhibitors, like sofosbuvir and daclatasvir, respectively, could be endowed with anti-SARS-CoV-2 activity. Methods SARS-CoV-2-infected

APA, Harvard, Vancouver, ISO, and other styles

2

Smith, Michael A., Randolph E. Regal, and Rima A. Mohammad. "Daclatasvir." Annals of Pharmacotherapy 50, no. 1 (2015): 39–46. http://dx.doi.org/10.1177/1060028015610342.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

CH., V. S. Gautam* N. Harika V. Balaji V. Srinivas Prasad. "METHOD DEVELOPMENT AND VALIDATION OF DACLATASVIR IN BULK & PHARMACEUTICAL DOSAGE FORM BY UV-VISIBLE SPECTROPHOTOMETRY." INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES 05, no. 03 (2018): 1980–85. https://doi.org/10.5281/zenodo.1213232.

Full text

Abstract:

Objective: The objective of the present work is to develop a simple, efficient, and reproducible spectrophotometric method for the quantitative estimation of hepatitis-C drug - Daclatasvir in active pharmaceutical ingredient(API) form and in pharmaceutical dosage form Methods: The developed ultraviolet spectrophotometric method for the quantitative estimation of hepatitis-C drugs - Daclatasvir based on measurement of absorption at a wavelength maximum (λmax) of 317 nm using methanol as solvent. Results: The method was validated in terms of, precision, linearity, accuracy, and robustness

APA, Harvard, Vancouver, ISO, and other styles

4

Ravindra S Morey, Ganesh G Tapadiya, and Manisha V Doud. "Development and validation of stability indicating HPTLC method for estimation of Daclatasvir Dihydrochloride in pharmaceutical dosage form." World Journal of Advanced Research and Reviews 23, no. 2 (2024): 2470–78. http://dx.doi.org/10.30574/wjarr.2024.23.2.2569.

Full text

Abstract:

A high-performance thin-layer chromatographic method was developed and validated for estimation of Daclatasvir Dihydrochloride in pharmaceutical dosage form. The proposed method was applied successfully to the pharmaceutical analysis of the recently approved dosage form of Daclatasvir Dihydrochloride which is available in market as a brand name of ‘NALDAC 60’ tablets. The drugs were satisfactorily show peak with RF 0.38 for Daclatasvir Dihydrochloride. Method was validated according to the ICH guidelines. The calibration plot was linear between 50-300 ng per band for Daclatasvir Dihydrochlorid

APA, Harvard, Vancouver, ISO, and other styles

5

Ravindra, S. Morey, G. Tapadiya Ganesh, and V. Doud Manisha. "Development and validation of stability indicating HPTLC method for estimation of Daclatasvir Dihydrochloride in pharmaceutical dosage form." World Journal of Advanced Research and Reviews 23, no. 2 (2024): 2470–78. https://doi.org/10.5281/zenodo.14891592.

Full text

Abstract:

A high-performance thin-layer chromatographic method was developed and validated for estimation of Daclatasvir Dihydrochloride in pharmaceutical dosage form. The proposed method was applied successfully to the pharmaceutical analysis of the recently approved dosage form of Daclatasvir Dihydrochloride which is available in market as a brand name of ‘NALDAC 60’ tablets. The drugs were satisfactorily show peak with RF 0.38 for Daclatasvir Dihydrochloride. Method was validated according to the ICH guidelines. The calibration plot was linear between 50-300 ng per band for Daclatasvir Di

APA, Harvard, Vancouver, ISO, and other styles

6

Reviriego, C. "Daclatasvir dihydrochloride." Drugs of the Future 36, no. 10 (2011): 735. http://dx.doi.org/10.1358/dof.2011.036.10.1703570.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Reviriego, C. "Daclatasvir dihydrochloride." Drugs of the Future 36, no. 10 (2011): 735. http://dx.doi.org/10.1358/dof.2011.36.10.1703570.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Chakravarthy, V. Ashok, Sailaja Bbv, and Praveen Kumar A. "METHOD DEVELOPMENT AND VALIDATION OF ULTRAVIOLET-VISIBLE SPECTROSCOPIC METHOD FOR THE ESTIMATION OF HEPATITIS-C DRUGS - DACLATASVIR AND SOFOSBUVIR IN ACTIVE PHARMACEUTICAL INGREDIENT FORM." Asian Journal of Pharmaceutical and Clinical Research 9, no. 9 (2016): 61. http://dx.doi.org/10.22159/ajpcr.2016.v9s3.14616.

Full text

Abstract:

ABSTRACTObjective: The objective of the present work is to develop a simple, efficient, and reproducible spectrophotometric method for the quantitativeestimation of hepatitis-C drugs - Daclatasvir and Sofosbuvir in its active pharmaceutical ingredient (API) form.Methods: The developed ultraviolet spectrophotometric method for the quantitative estimation of hepatitis-C drugs - Daclatasvir and Sofosbuvir isbased on measurement of absorption at a wavelength maximum (λmax) of 317 and 261 nm using methanol as solvent.Results: The method was validated in terms of specificity, precision, linearity, a

APA, Harvard, Vancouver, ISO, and other styles

9

SHULPEKOVA, Y. O., N. V. SHULPEKOVA, M. C. SEMENISTAYA, A. A. USANOVA, and C. S. PAVLOV. "TREATMENT OF HCV INFECTION BY A COMBINATION OF SOFOSBUVIR AND DACLATASVIR." Medical Council, no. 4 (May 26, 2017): 36–41. http://dx.doi.org/10.21518/2079-701x-2017-4-36-41.

Full text

Abstract:

The purpose of the review is to evaluate the efficacy and safety of using pangenotypic combination «of Sofosbuvir/Daclatasvir» — the direct action antiviral drugs in the treatment of chronic HCV infection at different stages of liver damage.Main provisions: Sofosbuvir is the antisense nucleotide, inhibiting RNA-dependent RNA-polymerase NS5B, this drug has earned a reputation as one of the strongest anti-replication drugs, including when there is interferon resistance. Daclatasvir is a powerful non-nucleotide inhibitor of NS5А protein, catalyzing formation of replicative complexes. Both compone

APA, Harvard, Vancouver, ISO, and other styles

10

Ahmad Ather, Ch Adnan, Mariyam Nawaz, Sohail Bashir Sulehria, Saadia Chaudary, Zara Mehmood, and Maria Rehman. ""TREATMENT SUCCESS OF SOFOSBUVIR AND DACLATSVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS OFHEPATITIS C VIRUS"." Journal of Akhtar Saeed Medical & Dental College 05, no. 02 (2023): 90–96. https://doi.org/10.51127/jamdcv5i2oa05.

Full text

Abstract:

Background:To compare the frequency of responders achieving SVR12 after taking sofosbuvir and daclatasvir with vs without ribavirin.Material and Methods:Total 180 patients meeting inclusion criteria were enrolled in the studyfromDepartment of Medicine, Government Teaching Hospital Shahdara, Lahore.This randomized controlled trial was conducted fromMarch 25, 2021,to September 24, 2021.Treatment naive cases were given tablet sofosbuvir & daclatasvir for 12 weeks. Treatment-experienced and naive with cirrhosis were given ribavirin based on their body weight along with sofosbuvir and daclatasv

APA, Harvard, Vancouver, ISO, and other styles

11

C. Damle, Mrinalini, and Nivedita B. Pawar. "STABILITY INDICATING HPLC METHOD FOR SOFOSBUVIR AND DACLATASVIR IN COMBINATION." Indian Drugs 59, no. 10 (2022): 74–79. http://dx.doi.org/10.53879/id.59.10.12506.

Full text

Abstract:

Direct acting fixed dose combination of sofosbuvir and daclatasvir to treat the viral hepatitis C disease is available in the market. So, a precise and robust stability indicating HPLC method for sofosbuvir and daclatasvir was developed. The SunQ C18 column (250 x 4.6 mm) was used for chromatographic separation with mobile phase consisting of 0.03 mM potassium dihydrogen phosphate buffer (pH 7): ACN (50: 50V/V). Optimised method satisfies the system suitability parameters with good resolution with 4.9 min Rt of sofosbuvir and 7.6 min Rt of daclatasvir. The method was validated as per ICH guide

APA, Harvard, Vancouver, ISO, and other styles

12

Ahmed, Hussien, Abdelrahman Ibrahim Abushouk, Mohamed Gadelkarim, Arwa Mohamed, Mohamed Gabr, and Ahmed Negida. "Efficacy of daclatasvir plus peginterferon alfa and ribavirin for patients with chronic hepatitis C genotype 4 infection." Bangladesh Journal of Pharmacology 12, no. 1 (2017): 12. http://dx.doi.org/10.3329/bjp.v12i1.29940.

Full text

Abstract:

<p class="Abstract">Clinical trials evaluating the safety and efficacy of daclatasvir for chronic hepatitis C virus (HCV) genotype 4 infection are scarce and yet with small sample sizes. Therefore, we conducted this systematic review to investigate the efficacy of daclatasvir in HCV genotype 4 treatment. A computer literature search of PubMed, Scopus, Embase, Ovid, Web of knowledge, and Cochrane central was conducted. We selected studies comparing daclatasvir plus peginterferon-alfa/ribavirin versus placebo plus peginterferon-alfa/ribavirin in patients with HCV genotype 4 infection. Pool

APA, Harvard, Vancouver, ISO, and other styles

13

Hanaa, Saleh Gamal H. Ragab Mohammed A. Othman. "STABILITY INDICATING HPLC METHOD DEVELOPMENT AND VALIDATION FOR DETERMINATION OF DACLATASVIR IN PURE AND TABLETS DOSAGE FORMS." iajps,csk publications 03, no. 12 (2017): 1565–72. https://doi.org/10.5281/zenodo.236131.

Full text

Abstract:

A sensitive, simple, selective and accurate HPLC method was developed and validated for analysis of antiviral drug Daclatasvir (BMS-790052, DCV) in pure form and in tablet dosage form in the presence of its degradation products. The chromatographic separation achieved by isocratic elution on Hypersil BDS C18, 4.6×150 mm, 5µm column at 25˚c. The mobile phase was a mixture of 0.05M Potassium dihydrogen phosphate (pH-4.5) and acetonitrile in ratio of 50:50 (v/v). The injection volume was 10µl. The flow rate was 1ml/ minute. The detection wavelength was 320 nm. The developed method was validated a

APA, Harvard, Vancouver, ISO, and other styles

14

Mobarak, Sara, Mehdi Salasi, Ahmad Hormati, et al. "Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER)." Journal of Antimicrobial Chemotherapy 77, no. 3 (2021): 758–66. http://dx.doi.org/10.1093/jac/dkab433.

Full text

Abstract:

Abstract Background The combination of sofosbuvir and daclatasvir has shown preliminary efficacy for hospitalized patients with COVID-19 in four open-label studies with small sample sizes. This larger trial aimed to assess if the addition of sofosbuvir/daclatasvir to standard care improved clinical outcomes in hospitalized patients with COVID-19. Methods This was a placebo-controlled, double-blind, randomized clinical trial in adults hospitalized with COVID-19 at 19 hospitals in Iran. Patients were randomized to oral sofosbuvir/daclatasvir 400/60 mg once-daily or placebo in addition to standar

APA, Harvard, Vancouver, ISO, and other styles

15

Eslami, Gholamali, Sajedeh Mousaviasl, Esmat Radmanesh, et al. "The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19." Journal of Antimicrobial Chemotherapy 75, no. 11 (2020): 3366–72. http://dx.doi.org/10.1093/jac/dkaa331.

Full text

Abstract:

Abstract Objectives Sofosbuvir and daclatasvir are direct-acting antivirals highly effective against hepatitis C virus. There is some in silico and in vitro evidence that suggests these agents may also be effective against SARS-CoV-2. This trial evaluated the effectiveness of sofosbuvir in combination with daclatasvir in treating patients with COVID-19. Methods Patients with a positive nasopharyngeal swab for SARS-CoV-2 on RT–PCR or bilateral multi-lobar ground-glass opacity on their chest CT and signs of severe COVID-19 were included. Subjects were divided into two arms with one arm receiving

APA, Harvard, Vancouver, ISO, and other styles

16

Barrail-Tran, Aurélie, Corine Vincent, Valérie Furlan, et al. "Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir." Antimicrobial Agents and Chemotherapy 59, no. 12 (2015): 7903–5. http://dx.doi.org/10.1128/aac.01603-15.

Full text

Abstract:

ABSTRACTRaltegravir pharmacokinetics was studied in 20 patients included in the ANRS HC30 QUADRIH Study before and after addition of anti-hepatitis C virus (anti-HCV) quadritherapy, including pegylated-interferon–ribavirin and asunaprevir plus daclatasvir. Raltegravir pharmacokinetic parameters remained unchanged whether administered on or off anti-HCV therapy. In addition, concentrations of raltegravir, asunaprevir, and daclatasvir were not affected by liver cirrhosis. These data suggest that in human immunodeficiency virus (HIV)-HCV-coinfected patients, whether cirrhotic or not, asunaprevir

APA, Harvard, Vancouver, ISO, and other styles

17

Garimella, T., R. Wang, W. L. Luo, et al. "Assessment of Drug-Drug Interactions between Daclatasvir and Methadone or Buprenorphine-Naloxone." Antimicrobial Agents and Chemotherapy 59, no. 9 (2015): 5503–10. http://dx.doi.org/10.1128/aac.00478-15.

Full text

Abstract:

ABSTRACTHepatitis C virus (HCV) infection is common among people who inject drugs, including those managed with maintenance opioids. Pharmacokinetic interactions between opioids and emerging oral HCV antivirals merit evaluation. Daclatasvir is a potent pangenotypic inhibitor of the HCV NS5A replication complex recently approved for HCV treatment in Europe and Japan in combination with other antivirals. The effect of steady-state daclatasvir (60 mg daily) on stable plasma exposure to oral opioids was assessed in non-HCV-infected subjects receiving methadone (40 to 120 mg;n= 14) or buprenorphine

APA, Harvard, Vancouver, ISO, and other styles

18

Godela, Ramreddy, and Sowjanya G. "Concurrent Determination of Daclatasvir and Sofosbuvir in Pure Binary Mixture and Their Combined Film Coated Tablets by a Simple Stability Indicating RP-HPLC Method." Research Journal of Pharmacy and Technology, November 30, 2021, 5913–18. http://dx.doi.org/10.52711/0974-360x.2021.01028.

Full text

Abstract:

A trouble-free, simple, specific and highly sensitive stability indicating phase HPLC method was developed for concurrent assessment of Daclatasvir and Sofosbuvir in pure and in their combined tablet formulation. An effectual separation was accomplished by using XDB Phenyl (250 x 4.6mm, 5µ,100 A0) column, mobile phase composition of Acetonitrile: buffer(0.1%v/v Trifluoroaceticacid in water) (50:50 v/v) and isocratic elution at a flow rate of 1ml/min and detection wavelength of 275nm. The extreme stress conditions like hydrolysis with acid and base, peroxide oxidation, thermal decomposition wer

APA, Harvard, Vancouver, ISO, and other styles

19

"Daclatasvir." Reactions Weekly 1641, no. 1 (2017): 102. http://dx.doi.org/10.1007/s40278-017-27016-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

"Daclatasvir." Reactions Weekly 1587, no. 1 (2016): 111. http://dx.doi.org/10.1007/s40278-016-14430-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

"Daclatasvir." Reactions Weekly 1802, no. 1 (2020): 113. http://dx.doi.org/10.1007/s40278-020-78031-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Elbadawy, Heba A., Sara A. Wahdan, and Ebtehal El-Demerdash. "Effect of atorvastatin on single oral pharmacokinetics and safety of daclatasvir in rats: Emphasis on P-glycoprotein and cytochrome P450." Current Drug Metabolism 23 (April 4, 2022). http://dx.doi.org/10.2174/1389200223666220404134524.

Full text

Abstract:

Objective: This study was aimed to investigate the effect of atorvastatin on daclatasvir oral pharmacokinetics and safety and assess the possible underlining mechanisms through targeting P-glycoprotein (P-gp) and cytochrome P450 (CYP3A4). Methods: The transport of daclatasvir, as well as the standard rhodamine 123 by P-gp across the rat intestine, was studied in vitro using the non-everted sac method. To assess the pharmacokinetic profile of daclatasvir in vivo, rats were divided into three groups receiving either saline, a standard P-gp inhibitor verapamil (25 mg/kg), or atorvastatin (10 mg/k

APA, Harvard, Vancouver, ISO, and other styles

23

Sayed, Rania A., Ahmed R. Mohamed, Wafaa S. Hassan, and Manal S. Elmasry. "Comparative study of four innovative earth-friendly platforms for rapid analysis of daclatasvir dihydrochloride: Application on different matrices." BMC Chemistry 17, no. 1 (2023). http://dx.doi.org/10.1186/s13065-023-00923-4.

Full text

Abstract:

Abstract Background Daclatasvir dihydrochloride has important roles not only in the management of COVID-19 pandemic symptoms but also in the treatment of chronic hepatitis C infection. Objective The current research presents four novel and simple platforms including silver-nanoparticles spectrophotometric technique and three electrochemical conductometric ones for daclatasvir analysis in its tablet, biological fluids, and dissolution media. Methods The spectrophotometric platform involved the synthesis of silvernanoparticles through a redox reaction between the reducing agent (daclatasvir) and

APA, Harvard, Vancouver, ISO, and other styles

24

Yamana, Anil Vikas, and Chandra Sekhar Kothapalli Bonnoth. "Validated Method development for estimation of Sofosbuvir and Daclatasvir in bulk and their dosage form by using RP-HPLC." Research Journal of Pharmacy and Technology, June 28, 2022, 2447–50. http://dx.doi.org/10.52711/0974-360x.2022.00408.

Full text

Abstract:

A simple, Accurate, precise method was developed for the simultaneous estimation of the Sofosbuvir and Daclatasvir in Tablet dosage form. Chromatogram was run through Standard Ascentis C18 150 x 4.6mm, 5m. Mobile phase containing Acetonitrile: Water taken in the ratio 60:40 was pumped through column at a flow rate of 0.7ml/min. Temperature was maintained at 30°C. Optimized wavelength selected was 279nm. Retention time of Sofosbuvir and Daclatasvir were found to be 2.198 min and 2.765 min. %RSD of the Sofosbuvir and Daclatasvir were and found to be 0.4 and 0.3 respectively. %Recovery was obtain

APA, Harvard, Vancouver, ISO, and other styles

25

"Daclatasvir/sofosbuvir." Reactions Weekly 1837, no. 1 (2021): 195. http://dx.doi.org/10.1007/s40278-021-88794-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

"Asunaprevir/daclatasvir." Reactions Weekly 1928, no. 1 (2022): 76. http://dx.doi.org/10.1007/s40278-022-25341-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

"Asunaprevir/daclatasvir." Reactions Weekly 1922, no. 1 (2022): 102. http://dx.doi.org/10.1007/s40278-022-22387-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

"Daclatasvir/sofosbuvir." Reactions Weekly 1879, no. 1 (2021): 119. http://dx.doi.org/10.1007/s40278-021-04603-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

"Asunaprevir/daclatasvir." Reactions Weekly 1583, no. 1 (2016): 155. http://dx.doi.org/10.1007/s40278-016-12718-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

"Asunaprevir/daclatasvir." Reactions Weekly 1586, no. 1 (2016): 51. http://dx.doi.org/10.1007/s40278-016-14077-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

"Asunaprevir/daclatasvir." Reactions Weekly 1687, no. 1 (2018): 44. http://dx.doi.org/10.1007/s40278-018-41465-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

"Asunaprevir/daclatasvir." Reactions Weekly 1688, no. 1 (2018): 34. http://dx.doi.org/10.1007/s40278-018-41669-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

"Daclatasvir/sofosbuvir." Reactions Weekly 1689, no. 1 (2018): 72. http://dx.doi.org/10.1007/s40278-018-41941-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

"Asunaprevir/daclatasvir." Reactions Weekly 1690, no. 1 (2018): 39. http://dx.doi.org/10.1007/s40278-018-42105-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

"Daclatasvir/sofosbuvir." Reactions Weekly 1692, no. 1 (2018): 125. http://dx.doi.org/10.1007/s40278-018-42653-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

"Asunaprevir/daclatasvir." Reactions Weekly 1693, no. 1 (2018): 70. http://dx.doi.org/10.1007/s40278-018-42960-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

"Asunaprevir/daclatasvir." Reactions Weekly 1696, no. 1 (2018): 49. http://dx.doi.org/10.1007/s40278-018-44237-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

"Asunaprevir/daclatasvir." Reactions Weekly 1706, no. 1 (2018): 64. http://dx.doi.org/10.1007/s40278-018-47393-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

"Asunaprevir/daclatasvir." Reactions Weekly 1707, no. 1 (2018): 55. http://dx.doi.org/10.1007/s40278-018-47871-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

"Daclatasvir/sofosbuvir." Reactions Weekly 1713, no. 1 (2018): 120. http://dx.doi.org/10.1007/s40278-018-49954-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

"Daclatasvir/sofosbuvir." Reactions Weekly 1713, no. 1 (2018): 121. http://dx.doi.org/10.1007/s40278-018-49955-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

"Asunaprevir/daclatasvir." Reactions Weekly 1714, no. 1 (2018): 61. http://dx.doi.org/10.1007/s40278-018-50241-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

"Asunaprevir/daclatasvir." Reactions Weekly 1717, no. 1 (2018): 52. http://dx.doi.org/10.1007/s40278-018-51122-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

"Daclatasvir/sofosbuvir." Reactions Weekly 1722, no. 1 (2018): 123. http://dx.doi.org/10.1007/s40278-018-52452-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

"Daclatasvir/simeprevir." Reactions Weekly 1629, no. 1 (2016): 96. http://dx.doi.org/10.1007/s40278-016-23368-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

"Asunaprevir/daclatasvir." Reactions Weekly 1631, no. 1 (2016): 32. http://dx.doi.org/10.1007/s40278-016-23810-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

"Asunaprevir/daclatasvir." Reactions Weekly 1633, no. 1 (2017): 91. http://dx.doi.org/10.1007/s40278-017-24362-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

"Daclatasvir/sofosbuvir." Reactions Weekly 1633, no. 1 (2017): 251. http://dx.doi.org/10.1007/s40278-017-24520-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

"Asunaprevir/daclatasvir." Reactions Weekly 1636, no. 1 (2017): 47. http://dx.doi.org/10.1007/s40278-017-25607-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

"Asunaprevir/daclatasvir." Reactions Weekly 1636, no. 1 (2017): 48. http://dx.doi.org/10.1007/s40278-017-25608-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!